Merck joins the TIGIT pivotal failure club
Keyvibe-010 fails, but not for the reason you might have expected.
Merus’s big bispecific test approaches
Hopes are high for petosemtamab head and neck data at ASCO, but what does a win look like?
ASCO 2024 preview – Astra’s plenary double
Abstract titles reveal some of ASCO’s key datasets.
How hot are antibody-drug conjugates?
An analysis of OncologyPipeline shows that $144bn has been pledged for ADCs since the start of 2022.
GSK’s $625m TIGIT bet approaches crunch time
Readout of the delayed Galaxies Lung-201 study is due imminently.
